Everolimus

Cat. No. M1709

Synonym:

RAD001, SDZ-RAD, Certican

Size	Price	Availability
Free Sample (0.5-1 mg)	USD 0	In stock
10mM*1mL	USD 66 USD66	In stock
5mg	USD 45 USD45	In stock
10mg	USD 66 USD66	In stock
50mg	USD 196 USD196	In stock

Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation

Purity: 100.0%
COA
MSDS
H-NMR
LC/MS

Product Information

Biological Activity

Everolimus (RAD001) also known as SDZ-RAD, Certican, Zortress and Afinitorm is an mTOR inhibitor with IC50 of 0.63 nM. Everolimus is an immunosuppressant analog of rapamycin (sirolimus) and inhibits growth factor-mediated proliferation of haematopoietic and nonhaematopoietic cells. Everolimus shows a potent inhibitory effect on posttransplant lymphoproliferative disorder (PTLD)-derived cells in vitro and in vivo.

Product Citations

Oncogene. 2020 Apr;39(15):3163-3178.

The EGFR-ZNF263 Signaling Axis Silences SIX3 in Glioblastoma Epigenetically
Everolimus purchased from AbMole
Pharmaceutics. 2020 Mar 13;12(3):260.

On-Chip Synthesis of Hyaluronic Acid-Based Nanoparticles for Selective Inhibition of CD44+ Human Mesenchymal Stem Cell Proliferation
Everolimus purchased from AbMole
Gynecol Oncol. 2019 Jun;153(3):661-669.

Chloride channel-3 is required for efficient tumour cell migration and invasion in human cervical squamous cell carcinoma.
Everolimus purchased from AbMole

Customer Product Validations & Biological Datas

	Source	Breast Cancer Res Treat (2015). Figure 2. Everolimus
	Method	flow cytometry
	Cell Lines	KPL-1 cell
	Concentrations	10 nM
	Incubation Time	5 d
	Results	Cells were exposed to everolimus at 10 nM for 5 days, and then flow cytometry was performed using Nim- DAPI staining. G0/G1 cell cycle arrest was observed in the two sensitive and the one intermediate cell line tested but was not observed in resistant lines

	Source	Breast Cancer Res Treat (2015). Figure 1. Everolimus
	Method	western blot
	Cell Lines	KPL-1 cell
	Concentrations	100 nM
	Incubation Time	10 min–48 h
	Results	We observed a significant inhibition of S6 phosphorylation in all tested cell lines after 30 min exposure to everolimus regardless of sensitivity to growth inhibitory effects.

Protocol (for reference only)

Cell Experiment
Cell lines	NCI-N87 and MKN45 cells
Preparation method	Proliferation assay. Gastric cancer cells (10,000 cells re-suspended in 1 ml medium) were seeded in 24-well plates. 24 h after seeding,0.5 ml medium containing RAD001 was added to yield desired concentrations of RAD001. At the time points indicated, gastric cancer cells were harvested and counted with a Coulter Z1 electronic cell counter (Beckman Coulter, UK).
Concentrations	2.5–160 n M
Incubation time	72 h

Animal Experiment
Animal models	NCI-N87 Tumor xenograft model with Pathogen-free, 4–6 week old, female CB-17 SCID mice
Formulation	saline
Dosages	5 mg/kg qd for 121 days
Administration	P.O

Chemical Information

Molecular Weight	958.22
Formula	C53H83NO14
CAS Number	159351-69-6
Solubility (25°C)	DMSO 30 mg/mL
Storage	Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month

Conversion of different model animals based on BSA (PMID: 27057123)

Species	Mouse	Rat	Rabbit	Guinea pig	Hamster	Dog
Weight (kg)	0.02	0.15	1.8	0.4	0.08	10
Body Surface Area (m²)	0.007	0.025	0.15	0.05	0.02	0.5
K_m factor	3	6	12	8	5	20

Animal A (mg/kg) = Animal B (mg/kg) multiplied by	Animal B K_m
	Animal A K_m

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the K_m factor for a mouse and then divide by the K_m factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Manzia et al. Transplant Proc. Everolimus and enteric-coated mycophenolate sodium ab initio after liver transplantation: midterm results.

[2] Caroti et al. Transplant Proc. Conversion from calcineurin inhibitors to everolimus with low-dose cyclosporine in renal transplant recipients with squamous cell carcinoma of the skin.

[3] Papadimitrakopoulou et al. J Thorac Oncol. Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer.

[4] Jensen et al. Am J Cardiol. Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the SORT OUT IV Trial).

[5] Arora et al. Am J Transplant. Virtual Histology Assessment of Cardiac Allograft Vasculopathy Following Introduction of Everolimus-Results of a Multicenter Trial.

[6] Saito et al. J Invasive Cardiol. Mid-Term Results of Everolimus-Eluting Stent in a Japanese Population Compared With a US Randomized Cohort: SPIRIT III Japan Registry With Harmonization by Doing.

[7] Holdaas et al. Expert Opin Drug Saf. A drug safety evaluation of everolimus in kidney transplantation.

Related mTOR Products
Zederone Zederone, a germacrane-type sesquiterpene, has potently cytotoxic against human white blood cancer cells and human prostate cancer cells. Zederone significantly inhibits the proliferation and downregulates the protein expressions of mTOR, and phosphorylated p70 S6 kinase (p-p70s6K) in SKOV3 cells.
MHY-1685 MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.
RMC-6272 RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors.
eCF309 eCF309 is a potent and highly selective mTOR inhibitor with remarkably low off-target activities (IC50 = 10-15 nM, both in vitro and in cells).
PQR626 PQR626, a rapamycin derivative, is a potent, selective, orally active, and brain-penetrant mTOR inhibitor, with an IC50 and Ki of 5 nM and 3.6 nM, respectively. PQR626 can be can be used for the research of neurological disorders.

Catalog

By Signaling Pathways

By Product Type

Signaling Pathways